14,15-cis-episulfide-eicosatrienoic acid, and 'epoxygenase' eicosanoid analog, inhibits ionophore- but not thrombin-induced platelet aggregation

K. Bernstrom, K. Malcolm, J. Mcgee, J. Maclouf, S. Levy-Toledano, J R Falck, F. A. Fitzpatrick

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

An 'epoxygenase' eicosanoid analog, 14,15-cis-episulfide-eicosatrienoic acid, has several unique pharmacological effects on platelets. These include (i) inhibition of ionophore A23187- but not thrombin-induced activation, (ii) inhibition of thromboxane B2 biosynthesis derived from endogenous but not exogenous arachidonic acid, and (iii) attenuation of ionophore-mediated increases in cytosolic Ca2+ when extracellular or membrane Ca2+ is available but not when these pools are excluded. Neither elevation of cyclic AMP levels, a potent inhibitory process, nor direct antagonism of the prostaglandin H2/thromboxane A2 receptor is responsible for the actions of 14,15-cis-episulfide-eicosatrienoic acid. These properties distinguish 14,15-cis-episulfide-eicosatrienoic acid from other antiaggregatory substances.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalMolecular Pharmacology
Volume39
Issue number2
StatePublished - 1991

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of '14,15-cis-episulfide-eicosatrienoic acid, and 'epoxygenase' eicosanoid analog, inhibits ionophore- but not thrombin-induced platelet aggregation'. Together they form a unique fingerprint.

Cite this